SCHEMBL17544506

SCHEMBL17544506

COc1cc(Nc2ncc(Br)c(NC3CC3)n2)cc(OC)c1OC

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 2/20 0.61
ULK1 O75385 7/20 0.56
ULK2 Q8IYT8 3/20 0.54
AURKA O14965 3/20 0.48
AURKB Q96GD4 3/20 0.48
KDR P35968 2/20 0.48
PRKAA2 P54646 1/20 0.48
PRKAA1 Q13131 1/20 0.48
IGF1R P08069 2/20 0.47
BRD4 O60885 2/20 0.46
KIT P10721 1/20 0.45
FLT3 P36888 1/20 0.45
CDK19 Q9BWU1 1/20 0.44
ALK Q9UM73 1/20 0.44
AXL P30530 1/20 0.44
TYRO3 Q06418 1/20 0.44
PLK1 P53350 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19654368 0.93 PTK2 (0.54) PTK2ULK1ULK2AURKAAURKB
SCHEMBL19654183 0.90 PTK2 (0.52) PTK2ULK1ULK2AURKAAURKB
SCHEMBL1116484 0.86 PTK2 (0.74) PTK2ULK1ULK2AURKAAURKB
SCHEMBL3494741 0.85 PTK2 (0.53) PTK2ULK1ULK2AURKAAURKB
SCHEMBL17547552 0.83 ULK1 (0.78) ULK1ULK2AURKAAURKBKDR
SCHEMBL19654369 0.82 ULK1 (0.53) PTK2ULK1ULK2AURKAAURKB
SCHEMBL17544503 0.80 PTK2 (0.76) PTK2ULK1ULK2KDRPRKAA2
SCHEMBL26506679 0.79 ULK1 (0.60) PTK2ULK1ULK2AURKAAURKB
SCHEMBL17544626 0.77 PTK2 (0.59) PTK2ULK1ULK2AURKAAURKB
SCHEMBL29575717 0.77 PTK2 (0.65) PTK2ULK1ULK2PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 US disclosed
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 US disclosed
EP-4070795-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2022-10-12 EP disclosed
EP-3185868-B1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INST FOR BIOLOGICAL STUDI (US) 2022-04-06 EP disclosed
WO-2021163633-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 WO disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
EP-3185868-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2017-07-05 EP disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 WO disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689397-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 PTK2 742/4885ULK1 1/4885ULK2 2/4885
US-10266549-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 PTK2 742/4885ULK1 1/4885ULK2 2/4885
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS ULK1, ULK2, ULK3 PTK2 613/4885ULK1 1/4885ULK2 2/4885
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 PTK2 884/4885ULK1 1/4885ULK2 2/4885
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 PTK2 884/4885ULK1 1/4885ULK2 2/4885
US-10774092-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 PTK2 742/4885ULK1 1/4885ULK2 2/4885
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 PTK2 884/4885ULK1 1/4885ULK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.